An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel

Thurneysen, S.; Cheng, Phil F.; Nagel, Hannes W.; Kunz, Michael; Jaberg-Bentele, Nicoletta F.; Nägeli, Mirjam; Ziegler, Mary E.; Guenova, Emmanuella; Goldinger, Simone M.; Mangana, Joanna; Levesque, Mitchell P.

doi:10.1111/bjd.14727

Cited by 9 publications

(10 citation statements)

References 51 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The CXCL13:CXCR5 axis has also been implicated in the initiation and progression of other solid tumors, such as ovarian cancer, melanoma, oral squamous cell carcinoma, osteosarcoma, thyroid cancer, and neuroblastoma (133–143). One interesting study showed that specific chemokine signatures may contribute to overall survival in wild-type and mutant p53 ovarian cancers, and CXCL13 was specifically associated with better overall survival (137).…”

Section: Cxcl13:cxcr5 Axis In Solid Tumorsmentioning

confidence: 99%

CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

2019

View full text Add to dashboard Cite

It is well-established that the chemokine C-X-C motif ligand 13 (CXCL13) and its receptor, the G-protein coupled receptor (GPCR) CXCR5, play fundamental roles in inflammatory, infectious and immune responses. Originally identified as a B-cell chemoattractant, CXCL13 exerts important functions in lymphoid neogenesis, and has been widely implicated in the pathogenesis of a number of autoimmune diseases and inflammatory conditions, as well as in lymphoproliferative disorders. Current evidence also indicates that the CXCL13:CXCR5 axis orchestrates cell-cell interactions that regulate lymphocyte infiltration within the tumor microenvironment, thereby determining responsiveness to cytotoxic and immune-targeted therapies. In this review, we provide a comprehensive perspective of the involvement of CXCL13 and its receptor in cancer progression. Studies in recent years postulated novel roles for this chemokine in controlling the cancer cell phenotype, and suggest important functions in the growth and metastatic dissemination of solid tumors. Carcinogens have been found to induce CXCL13 production, and production of this chemokine within the tumor milieu has been shown to impact the proliferation, migration, and invasive properties of cancer cells. Thus, the complex networks of cellular interactions involving tumoral CXCL13 and CXCR5 integrate to promote cancer cell autonomous and non-autonomous responses, highlighting the relevance of autocrine and paracrine interactions in dictating the cancer phenotype. Dissecting the molecular and signaling events regulated by CXCL13 and how this chemokine dynamically controls the interaction between the cancer cell and the tumor microenvironment is key to identify novel effectors and therapeutic targets for cancer treatment.

show abstract

Section: Cxcl13:cxcr5 Axis In Solid Tumorsmentioning

confidence: 99%

CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

2019

View full text Add to dashboard Cite

show abstract

“…An open‐label, investigator‐led pilot study by Thurneysen et al . demonstrated that while there was no objective response to combination treatment of patients with pazopanib, a multitarget tyrosine kinase inhibitor with selectivity for VEGF receptors, and paclitaxel, a microtubule‐stabilizing drug that induces mitotic arrest, there was a dramatic increase in recruitment of tumour‐associated macrophages, as well as an increase in tumour‐promoting cytokines in response to the pazopanib–paclitaxel combination treatment . The group hypothesize that macrophage‐mediated tumour cell protection may limit the efficacy of pazopanib‐induced growth inhibition and cell death, which they indicate may be overcome by targeting macrophages with compounds such as the monoclonal antibody to colony stimulating factor‐1, emactuzumab.…”

mentioning

confidence: 77%

How breakthroughs in translational research have impacted treatment strategies for melanoma

2018

View full text Add to dashboard Cite

“… 7 The chemokines they encode are secreted by macrophages for neutrophil recruitment in the presence of necrotic cells. 8 , 9 Both exert their signal through the same receptor, CXCR2. Studies have shown that high expression of these genes is associated with poor prognosis in a number of cancers, such as in colorectal cancer.…”

Section: Discussionmentioning

confidence: 99%

Four Immune Modulating Genes in Primary Melanoma That Predict Metastatic Potential

Erdrich¹,

Lourdault²,

Judd³

et al. 2022

Journal of Surgical Research

View full text Add to dashboard Cite

An exploratory study investigating the metabolic activity and local cytokine profile in patients with melanoma treated with pazopanib and paclitaxel

Abstract: In this patient population pazopanib efficacy was limited. Response is associated with low M2-like macrophage density and increased expression of several chemokines.

Cited by 9 publications

References 51 publications

CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

CXCL13 and Its Receptor CXCR5 in Cancer: Inflammation, Immune Response, and Beyond

How breakthroughs in translational research have impacted treatment strategies for melanoma

Four Immune Modulating Genes in Primary Melanoma That Predict Metastatic Potential

Contact Info

Product

Resources

About